Yun Rose Li, M.D., Ph.D. (IMAGE)

City of Hope

Yun Rose Li, M.D., Ph.D.

Caption

City of Hope has opened a phase 2 clinical trial comparing three different strategies for protecting heart health in prostate cancer patients who receive androgen deprivation therapy (ADT), a potentially lifesaving hormone therapy. “ADT is a cornerstone of prostate cancer treatment, but it can have significant unintended effects on cardiometabolic health,” said principal investigator Yun Rose Li, M.D., Ph.D., assistant professor and physician-scientist in the Department of Radiation Oncology at City of Hope. “Addressing these metabolic and cardiovascular consequences is essential to improving overall health, reducing long-term morbidity and optimizing outcomes for patients undergoing cancer therapy.”  

Credit

City of Hope

Usage Restrictions

Please use photo credit

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.